Most Read Articles
Yesterday
Podcast: Dr Shamir Mehta briefly discusses the clinical impact of findings from the COMPLETE trial
Yesterday
Podcast: Prof Derek Chew explains the importance of a 1-hour troponin T protocol in suspected ACS as discussed in the RAPID-TnT trial
Yesterday
Sodium-glucose transport protein 2 (SGLT2) inhibitors exert a putative epigenetic regulation of the protecting cardiovascular effect, reports a study, adding that dapagliflozin may protect the kidneys by preserving renal vasodilating capacity.
Pank Jit Sin, 5 days ago

The Malaysian Endocrine and Metabolic Society (MEMS) and Malaysian Diabetes Educators Society (MDES) jointly launched the For Your Sweetheart campaign—a nationwide endeavour to increase public awareness and to educate Malaysians about diabetes-related heart disease. 

Vitamin D3 supplementation not an effective defence strategy against diabetes

14 Aug 2019

Supplementation with vitamin D3 at a dose of 4,000 IU per day does not significantly stave off the risk of diabetes in high-risk individuals with or without vitamin D insufficiency, according to data from the Vitamin D and Type 2 Diabetes (D2D) trial.

D2D randomized 2,423 adults free of diabetes but who met at least two of three glycaemic criteria for prediabetes (fasting plasma glucose level, 100–125 mg/dl; plasma glucose level 2 hours after a 75-g oral glucose load, 140–199 mg/dl; and HbA1c level, 5.7–6.4 percent) to receive either 4,000 IU per day of vitamin D3 (n=1,211) or placebo, regardless of the baseline serum 25-hydroxyvitamin D level.

By month 24, the mean serum 25-hydroxyvitamin D level increased in the vitamin D group (from 27.7 ng/ml at baseline to 54.3 ng/ml) but remained stable in the placebo group (from 28.2 ng/ml at baseline to 28.8 ng/ml).

Over a median follow-up of 2.5 years, the primary outcome of new-onset diabetes occurred in 293 participants in the vitamin D group and 323 in the placebo group, resulting in incidence rates of 9.39 and 10.66 events per 100 person-years, respectively. Cox analysis showed that vitamin D supplementation did not lead to a significant reduction in the risk of incident diabetes (hazard ratio, 0.88, 95 percent CI, 0.75–1.04; p=0.12).

The incidence of adverse events (AEs) such as hypercalcaemia, fasting urine calcium:creatinine ratio of >0.375, low estimated glomerular filtration rate and nephrolithiasis, was comparable between the two groups. Overall, AEs led to trial withdrawal in 47 participants (3.9 percent) in the vitamin D group vs 37 (3.1 percent) in the placebo group (difference, 0.8 percentage points).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Yesterday
Podcast: Dr Shamir Mehta briefly discusses the clinical impact of findings from the COMPLETE trial
Yesterday
Podcast: Prof Derek Chew explains the importance of a 1-hour troponin T protocol in suspected ACS as discussed in the RAPID-TnT trial
Yesterday
Sodium-glucose transport protein 2 (SGLT2) inhibitors exert a putative epigenetic regulation of the protecting cardiovascular effect, reports a study, adding that dapagliflozin may protect the kidneys by preserving renal vasodilating capacity.
Pank Jit Sin, 5 days ago

The Malaysian Endocrine and Metabolic Society (MEMS) and Malaysian Diabetes Educators Society (MDES) jointly launched the For Your Sweetheart campaign—a nationwide endeavour to increase public awareness and to educate Malaysians about diabetes-related heart disease.